Bayesian network analyses of resistance pathways against efavirenz and nevirapine

AIDS

Volumn 22, Issue 16, 2008, Pages 2107-2115

  Deforche, Koen ^a   Camacho, Ricardo J ^b   Grossman, Zehave ^c   Soares, Marcelo A ^d   Van Laethem, Kristel ^a   Katzenstein, David A ^e   Harrigan, P Richard ^f   Kantor, Rami ^g   Shafer, Robert ^e   Vandamme, Anne Mieke ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b Centro Hospitalar de Lisboa Ocidental   (Portugal)

^c MINISTRY OF HEALTH   (Israel)

^d FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^g BROWN UNIVERSITY   (United States)

Author keywords

Bayesian network; Efavirenz; HIV 1 antiviral resistance; Nevirapine

Indexed keywords

EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; TENOFOVIR;

ANTIVIRAL RESISTANCE; ARTICLE; BAYES THEOREM; CONTROLLED STUDY; DRUG TREATMENT FAILURE; GENETIC POLYMORPHISM; HUMAN IMMUNODEFICIENCY VIRUS 1; PREVALENCE; PRIORITY JOURNAL; VIRUS MUTATION;

ANTI-HIV AGENTS; BAYES THEOREM; BENZOXAZINES; DATABASES, FACTUAL; DRUG RESISTANCE, VIRAL; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MUTATION; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 55249096269     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32830fe940     Document Type: Article

References (32)

1. Shafer RW. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev 2002; 15:247-277.
2. Van Laethem K, De Luca A, Antinori A, Cingolani A, Perno CF, Vandamme AM. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1 infected patients. Antivir Ther 2002; 7:1359-6535.
3. Frater AJ, Beardall A, Ariyoshi K, Churchill D, Galpin S, Clarke JR, et al. Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients. AIDS 2001; 15:1493-1502.
4. Parkin NT, Schapiro JM. Antiretroviral drug resistance in non-subtype B HIV-1, HIV-2 and SIV. Antivir Ther 2004; 9:3-12.
5. Brindeiro PA, Brindeiro RM, Mortensen C, Hertogs K, De Vroey V, Rubini NPM, et al. Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy. J Clin Microbiol 2002; 40:4512-4519.
6. Ariyoshi K, Matsuda M, Miura H, Tateishi S, Yamada K, Sugiura W. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection. J Acquir Immune Defic Syndr 2003; 33:336-342.
7. Grossman Z, Vardinon N, Chemtob D, Alkan ML, Bentwich Z, Burke M, et al. Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B. AIDS 2001; 15:1453-1460.
8. Grossman Z, Istomin V, Averbuch D, Lorber M, Risenberg K, Levi I, et al., Israel AIDS Multi-Center Study Group. Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C. AIDS 2004; 18:909-915.
9. Camacho RJ, Vandamme AM. Antiretroviral resistance in different HIV-1 subtypes: impact on therapy outcomes and resistance testing interpretation. Curr Opin HIV AIDS 2007; 2:123-129.
10. van de Vijver DA, Wensing AMJ, Angarano G, Asjö B, Balotta C, Boeri E, et al. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. J Acquir Immune Defic Syndr 2006; 41:352-360.
11. Deforche K, Silander T, Camacho R, Grossman Z, Soares MA, Van Laethem K, et al. Analysis of HIV-1 pol sequences using Bayesian Networks: implications for drug resistance. Bioinformatics 2006; 22:2975-2979.
12. WHO. Towards universal access by 2010: how WHO is working with countries to scale-up HIV prevention, treatment, care and support. Geneva: WHO; 2006.
13. Johnson VA, Brun-Vénizet F, Bonaventura C, Günthard H, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007; 15:119-125.
14. de Oliveira T, Deforche K, Cassol S, Salminen M, Paraskevis D, Seebregts C, et al. An automated genotyping system for analysis of HIV-1 and other microbial sequences. Bioinformatics 2005; 21:3797-3800.
15. Friedman N, Goldszmidt M, Wyner AJ. Data analysis with Bayesian networks: a bootstrap approach. In: Proceedings of UAI-99. San Francisco, CA, 1999. pp. 206-215.
16. Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, Carobene M, et al. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to nonnucleoside reverse transcriptase inhibitors. AIDS 2003; 17:F1-F15.
17. Saracino A, Monno L, Scudeller L, Cibelli DC, Tartaglia A, Punzi G, et al. Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors. J Med Virol 2006; 78:9-17.
18. Svicher V, Sing T, Santoro MM, Forbici F, RodrÃguez-Barrios F, Bertoli A, et al. Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J Virol 2006; 80:7186-7198.
19. Rhee SY, Fessel WJ, Zolopa AR, Hurley L, Liu T, Taylor J, et al. HIV-1 protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. J Infect Dis 2005; 192:456-465.
20. Cane PA, Green H, Fearnhill E, Dunn D, and the UK collaborative group on HIV drug resistance. Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. AIDS 2007; 21:447-455.
21. Ceccherini-Silberstein F, Svicher V, Sing T, Artese A, Santoro MM, Forbici F, et al. Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors. J Virol 2007; 81:11507-11519.
22. Parkin NT, Gupta S, Chappey C, Petropoulos CJ. The K101P and K103R/V179D mutations in human immunodeficiency virus type 1 reverse transcriptase confer resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2006; 50:351-354.
23. Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Toure-Kane C, et al. Genetic diversity of protease and reverse transcriptase sequences in nonsubtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000; 38:3919-3925.
24. Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994; 68:1660-1666.
25. Selmi B, Deval J, Alvarez K, Boretto J, Sarfati S, Guerreiro C, et al. The Y181C substitution in 3′-azido-3′-deoxythymidine- resistant human immunodeficiency virus, type 1, reverse transcriptase suppresses the ATP-mediated repair of the 3′-azido-3′-deoxythymidine 5′-monophosphate-terminated primer. J Biol Chem 2003; 278:40464-40472.
26. Boyer PL, Gao HQ, Hughes SH. A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer. Antimicrob Agents Chemother 1998; 42:447-452.
27. Ren J, Milton J, Weaver KL, Short SA, Stuart DI, Stammers DK. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure 2000; 8:1089-1094.
28. Turner D, Brenner B, Wainberg MA. Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1. Clin Diagn Lab Immunol 2003; 10:979-981.
29. Hsu M, Inouye P, Rezende L, Richard N, Li Z, Prasad VR, et al. Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1. Nucleic Acids Res 1997; 25:4532-4536.
30. Shulman N, Zolopa AR, Passaro D, Shafer RW, Huang W, Katzenstein D, et al. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. AIDS 2001; 15:1125-1132.
31. Shulman NS, Bosch RJ, Mellors JW, Albrecht MA, Katzenstein DA. Genetic correlates of efavirenz hypersusceptibility. AIDS 2004; 18:1781-1785.
32. Jones J, Taylor B, Wilkin TJ, Hammer SM. Advances in anti-retroviral therapy. Top HIV Med 2007; 15:48-82.